Literature DB >> 27503183

Febuxostat in Hyperuricemic Patients With Advanced CKD.

Doo-Ho Lim1, Ji Seon Oh2, Soo Min Ahn1, Seokchan Hong1, Yong-Gil Kim1, Chang-Keun Lee1, Seung Won Choi2, Bin Yoo3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27503183     DOI： 10.1053/j.ajkd.2016.07.001

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  4 in total

1.  Management of Gout and Hyperuricemia in CKD.

Authors:  Ana Beatriz Vargas-Santos; Tuhina Neogi
Journal:  Am J Kidney Dis       Date:  2017-04-26       Impact factor: 8.860

Review 2.  Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review.

Authors:  Hamish Farquhar; Ana B Vargas-Santos; Huai Leng Pisaniello; Mark Fisher; Catherine Hill; Angelo L Gaffo; Lisa K Stamp
Journal:  Rheumatol Adv Pract       Date:  2021-01-04

Review 3.  Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat.

Authors:  Andreas Jordan; Ursula Gresser
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-25

Review 4.  Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.

Authors:  Lisa K Stamp; Hamish Farquhar; Huai Leng Pisaniello; Ana B Vargas-Santos; Mark Fisher; David B Mount; Hyon K Choi; Robert Terkeltaub; Catherine L Hill; Angelo L Gaffo
Journal:  Nat Rev Rheumatol       Date:  2021-07-30       Impact factor: 20.543
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.